36BB
Structure of BA.4-S-RBD/Ab#10-M30W-S94M
36BB の概要
| エントリーDOI | 10.2210/pdb36bb/pdb |
| EMDBエントリー | 77348 |
| 分子名称 | Ab#10-M30W-S94M heavy chain, Ab#10-M30W-S94M light chain, Spike protein (3 entities in total) |
| 機能のキーワード | sars-cov-2, viral protein |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 3 |
| 化学式量合計 | 100217.78 |
| 構造登録者 | |
| 主引用文献 | Pallesen, J.,Du, J.,Wu, Y.,Ghosh, S.,Bayruns, K.,Sadeesh, R.,Weiner, D. Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants. Res Sq, 2026 Cited by PubMed Abstract: The ongoing evolution of SARS-CoV-2, particularly the emergence of Omicron subvariants, compromised the effectiveness of many therapeutic antibodies. In this study, we employed a structure-guided computational design strategy to systematically optimize the COV2-2196 antibody for improved neutralization of Omicron variants. Through iterative rounds of computational design and experimental validation, we identified key paratope mutations that restored and enhanced antibody binding and neutralization potency against resistant viral strains. Cryo-EM structural analysis revealed the molecular basis for these improvements, highlighting how targeted modifications can accommodate epitope changes introduced by viral evolution. Our approach demonstrates that effective antibody optimization can be achieved using accessible computational resources, providing a practical framework for rapid therapeutic development. These findings underscore the potential of structure-based design to address challenges posed by viral antigenic drift and support the development of broadly effective antibody therapeutics for emerging infectious diseases. PubMed: 42396495DOI: 10.21203/rs.3.rs-9917568/v1 主引用文献が同じPDBエントリー |
| 実験手法 | ELECTRON MICROSCOPY (3.6 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






